Vaxcyte director granted RSUs and stock options

Vaxcyte, Inc. director Teri Loxam reported receiving equity-based compensation.

Rhea-AI Filing Summary

Vaxcyte, Inc. director Teri Loxam reported receiving equity-based compensation. The filing shows a grant of 2,265 shares of Common Stock underlying restricted stock units (RSUs) and a separate grant of stock options covering 11,389 shares of Common Stock.

The RSUs vest in full on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service, and delivery has been deferred under the company’s Nonqualified RSU Deferral Program for Non-Employee Directors. The stock options have an exercise price of $49.56 per share, vest monthly on the same schedule, and expire on June 15, 2036. Following the RSU grant, Loxam directly holds 12,481 shares of Common Stock.

Insider Trade Summary

Grant/Award: 13,654 shares

Grant/Award 2 txns

Insider Loxam Teri

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,389	$0.00	$0.00
Grant/Award	Common Stock	2,265	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 11,389 contracts (Direct); Common Stock — 12,481 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control .
2. F2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Key Figures

RSU grant: 2,265 shares Option grant size: 11,389 shares Option exercise price: $49.56/share +2 more

5 metrics

RSU grant 2,265 shares Common Stock underlying RSUs granted to director

Option grant size 11,389 shares Stock options for Common Stock granted to director

Option exercise price $49.56/share Exercise price for granted stock options

Option expiration June 15, 2036 Expiration date of stock options

Shares held after grant 12,481 shares Common Stock directly held after RSU grant

Key Terms

restricted stock units ("RSUs"), Nonqualified RSU Deferral Program for Non-Employee Directors, separation from service, qualifying change in control, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Nonqualified RSU Deferral Program for Non-Employee Directors financial

"Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery..."

separation from service financial

"deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control"

qualifying change in control financial

"deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control"

Stock Option (right to buy) financial

"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vaxcyte (PCVX) director Teri Loxam report?

Teri Loxam reported receiving equity compensation grants, not open-market trades. The filing shows new RSUs tied to Common Stock and a separate stock option grant, both contingent on continued board service and standard vesting conditions.

How many Vaxcyte (PCVX) RSUs did Teri Loxam receive in this Form 4?

The filing shows 2,265 shares of Vaxcyte Common Stock underlying restricted stock units. Each RSU represents a contingent right to one share, vesting in full on a future date tied to board service and the company’s annual meeting schedule.

What stock options were granted to Teri Loxam by Vaxcyte (PCVX)?

Loxam received stock options for 11,389 shares of Vaxcyte Common Stock at an exercise price of $49.56 per share. These options vest monthly and are scheduled to be fully vested by June 15, 2027, subject to continuous service.

When do Teri Loxam’s Vaxcyte (PCVX) RSUs and options vest?

Both the RSUs and options will fully vest on the earlier of June 15, 2027 or the day before Vaxcyte’s next annual stockholder meeting. Vesting is subject to acceleration provisions and Loxam’s continuous service as described in the filing footnotes.

What is the deferral arrangement for Teri Loxam’s Vaxcyte (PCVX) RSUs?

Under Vaxcyte’s Nonqualified RSU Deferral Program for Non-Employee Directors, Loxam has deferred delivery of all vested RSUs. Shares will be delivered at the earlier of a separation from service or a qualifying change in control, according to the footnote.

How many Vaxcyte (PCVX) shares does Teri Loxam hold after this Form 4?

After the reported RSU grant, Loxam directly holds 12,481 shares of Vaxcyte Common Stock. This figure reflects her direct non-derivative holdings following the transaction, separate from the newly granted but unexercised stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loxam Teri

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, STE. 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		A		2,265(1)	A	$0	12,481	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$49.56	06/15/2026		A		11,389		(2)	06/15/2036	Common Stock	11,389	$0	11,389	D

Explanation of Responses:

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control .

2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

Remarks:

	Teri Loxam, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)